Lupin Receives FDA Approval for Generic Ortho Tri-cyclen Lo® Tablets
MUMBAI and BALTIMORE, July 3, 2012 /PRNewswire/ --
BSE : 500257
BLOOMBERG: LPC IN
Pharma major, Lupin Ltd., announced today that its subsidiary, Lupin Pharmaceuticals Inc. (collectively, Lupin) has received approval for its Norgestimate and Ethinyl Estradiol Tablets, 0.18 mg/0.025 mg, 0.215 mg/0.025 mg, and 0.25 mg/0.025 mg from the United States Food and Drugs Administration (FDA).
Lupin's Norgestimate and Ethinyl Estradiol Tablets are the AB-rated generic equivalent of Ortho Tri-cyclen Lo® Tablets,0.18 mg/0.025 mg, 0.215 mg/0.025 mg, and 0.25 mg/0.025 mg, of Janssen Pharmaceuticals, Inc.. Norgestimate and Ethinyl Estradiol Tablets are indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception.
Ortho Tri-cyclen Lo® Tablets had annual U.S sales of approximately US$ 421 million for the twelve months ending March 2012 (IMS Health sales data).
About Lupin Limited
Headquartered in Mumbai, Lupin is an innovation led transnational pharmaceutical company producing a wide range of generic and branded formulations and APIs. The Company today has significant presence in the Cardiovascular, Diabetology, Asthma, Paediatrics, CNS, GI, Anti-Infective and NSAID space in addition to holding global leadership positions in the Anti-TB and Cephalosporin segments.
Lupin is the 5th largest and fastest growing generics player in the US (5.1% market share by prescriptions, IMS Health), the only Asian company to achieve that distinction. The company is also the fastest growing top 10 pharmaceutical player in India, Japan and South Africa (IMS).
For the financial year ended March 2012, Lupin's Consolidated Revenues and Profit after Tax were Rs.70,829 Million (USD 1.42 Billion) and Rs. 8,676 Million (USD 190 million) respectively. Please visit http://www.lupinworld.com for more information.
Lupin Pharmaceuticals, Inc. is the wholly owned U.S. subsidiary of Lupin Limited. Headquartered in Baltimore, Maryland, Lupin Pharmaceuticals, Inc. is dedicated to delivering high-quality, affordable generic medicines and branded formulations trusted by healthcare professionals and patients across geographies. For more information, visit http://www.lupinpharmaceuticals.com.
*Ortho Tri-cyclen Lo Tablet® are a registered copyright of Janssen Pharmaceuticals, Inc..
For further information or queries, please contact -
Head - Corporate Communications
SOURCE Lupin Ltd
More by this Source
Lupin Launches Generic Aciphex® Delayed-Release Tablets, 20 mg in the US
Nov 11, 2013, 07:07 ET
Lupin Receives FDA Approval for its New Drug Application for Antara® Capsules
Oct 22, 2013, 12:42 ET
Lupin Launches Generic ZYMAXID™ Ophthalmic Solution in the US
Oct 03, 2013, 10:26 ET
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.